Maryland cannabis shoppers could eventually get a closer look—and smell—before buying flower under a proposed regulatory package now moving through state review. The Maryland Cannabis Administration says the display provision would allow visual and olfactory inspection under security requirements. It also expressly warns licensees not to implement that change before the regulation takes effect, anticipated in early 2027.

That timing is the most useful detail for anyone expecting open display jars on a dispensary counter today. A proposal about the shopping experience is not immediate authorization. The current update outlines what the agency wants to change and the process still ahead, including a formal public-comment period.

What Maryland has actually submitted

On its laws and regulations page, MCA says it submitted a Notice of Proposed Action to the Administrative, Executive and Legislative Review Committee on October 24. The agency says that followed a 15-day informal posting, during which it received stakeholder feedback and incorporated some recommendations.

MCA anticipates publication in the Maryland Register on November 30, followed by 30 days for formal public comment. Those are the agency’s stated expectations, rather than a guarantee that every proposed provision will emerge unchanged or take effect on a particular day. Readers should check the eventual published notice and final effective date before treating the package as operative rules.

Cannabis News reported the proposed package on November 1. The primary agency update provides the clearest distinction between the submitted changes and the rules dispensaries can use now.

A display jar is one part of the purchase

The proposed provision concerns seeing and smelling cannabis. It does not describe a right to handle unrestricted inventory or consume a sample. MCA’s summary attaches security requirements and explicitly separates the proposal from implementation. Customers should therefore follow the store’s current procedures rather than assume a news story creates a new sampling option.

As a shopping matter, a better view can help a customer formulate questions about a product. It cannot by itself settle what the product contains, whether it fits a particular person’s needs or what effects that person will experience. A sensory impression and the information on a regulated product label answer different questions.

A useful conversation at the counter can keep both in view: what is the product, what does its labeling say, and what information can staff provide about it? None of those questions requires pretending that a visual inspection is a laboratory test or that aroma is a medical recommendation.

Staffing changes have a separate legal history

The same proposed package would update the micro-dispensary employee limit from 10 to 20, implementing Chapter 375 of 2026. The General Assembly’s HB 622 record identifies that measure as approved by the governor on May 12, with a July 1 effective date.

That distinction matters. The staffing increase comes from an enacted law; the display-jar change is presented in a regulatory proposal with its own implementation warning. Bundling them into one announcement does not give them identical legal origins or make the entire package newly effective on the day of a news report.

The bill also addressed cannabis agent training and certain medical delivery provisions. In the proposed amendments, MCA describes replacing its Responsible Vendor Training program with a Cannabis Agent Training program and setting minimum requirements. For operators, that makes the package broader than a change in merchandising equipment.

Packaging and customer information also matter

Another proposed change would require allergens on the outer marketing layer of cannabis packaging. Alongside the display proposal, that points to two different stages of evaluating a product: encountering it at the counter and reading the information that accompanies the purchase. One should complement the other, rather than make label details less important.

MCA also proposes a process for documentation supporting advertising audience-composition claims and a range of licensing and technical clarifications. The notice also addresses customer-related information beyond the sales floor. MCA says it would codify restrictions on disclosing sociological information for immigration enforcement without a valid warrant. That privacy provision sits alongside commercial rules in the same package, illustrating why stakeholders should examine the proposal as a whole instead of responding only to the most visible retail change.

Businesses considering operational changes should read the complete notice when published, because an attractive consumer-facing headline will not capture every obligation affecting a store.

Our Eldersburg dispensary opening coverage looks at the physical retail footprint. This proposal addresses how parts of that retail experience may work. For now, the practical takeaway is straightforward: Maryland is considering secure sensory displays, while shoppers and licensees still need to distinguish proposed options from current permissions.

Illustrative stock cannabis photograph; not a Maryland dispensary or an approved display device. Photo: Terrance Barksdale / Pexels.

Tokyo’s International Cannabis Film Festival is preparing its fifth edition for November 29 at LOFT9 Shibuya, with a special screening of Cheech & Chong’s Last Movie. The cannabis connection is central to the program: organizers are using cinema to bring the plant’s cultural history into conversation with comedy, music and Japan’s hemp traditions.

The festival’s current announcement describes screenings, talks, international dialogue and music. It is a November event preview, rather than a newly announced film premiere. The anniversary screening was announced in August, and the film itself belongs to an earlier release cycle. What makes it timely now is the approaching Tokyo event and its still-developing visitor arrangements.

A familiar duo in a different setting

Distributor DECAL’s film page identifies David Bushell as the director and Cheech Marin and Tommy Chong as the stars of the 2025 documentary. Its description presents their relationship through animation, archive material and a road-trip framework. That provides a factual sense of the film’s approach without pretending we have screened it for this report.

For a cannabis publication, the pairing is especially natural: a festival named for the plant is presenting a film about performers closely associated with its screen culture. The interesting question is what happens when that cultural reference travels. Viewers can recognize familiar comedy while considering how its history is understood by a different audience, in a different city.

The screening announcement does not establish that Marin, Chong or Bushell will attend in person. The confirmed attraction is the film and the program described by the organizers. Guest appearances, screening language, accessibility arrangements and a detailed running order should come from subsequent official event information.

The anniversary is about a conversation

In its anniversary and partnership materials, TICFF describes a forum connecting film with medicine, history, art, music and public dialogue. The organizers frame the Cheech & Chong screening as a bridge between global counterculture and Japan’s own relationship with hemp and urban culture.

Those are the organizers’ goals for the event, rather than proof that a screening can resolve political or medical debates. What the format can offer is a shared work to discuss. A film gives people a particular story, set of characters and creative choices to respond to, rather than asking them to agree on everything the word cannabis can mean.

That makes this a culture story with a concrete plant connection. It also creates room for viewers whose interests differ: someone may come for documentary craft, another for comedy history and another for the festival’s wider subject. The program need not flatten those interests into a single viewpoint to be worth following.

Online voting follows its own calendar

The festival’s selection and awards guide distinguishes jury awards from the Audience Award. The selection team chooses the official selections; jurors consider the films and reach final decisions through deliberation. The audience award is chosen separately by registered viewers.

Online viewing and voting are expected to open around November 15, with voting due to close March 20, 2027, and results announced at the end of March. The proposed viewing period extends beyond the Tokyo festival and includes later caravan screenings. Registration and a participant ID are part of the online process.

For a reader outside Japan, that could provide a way to follow selected films without a trip to Shibuya. It does not mean every part of the November 29 program will stream. In particular, the special anniversary screening should not be assumed to be included merely because an online audience competition exists.

What to confirm before making plans

As checked November 3, the official site says ticketing for the Tokyo main event is still being arranged. It treats those tickets separately from online viewing registration. Anyone considering attending should look for the official on-sale announcement before committing to a screening itinerary around an assumed ticket or start time.

The venue is listed as LOFT9 Shibuya in KINOHAUS, at 1-5 Maruyamacho. That establishes where organizers plan to hold the event, but a cannabis-themed cultural program is not permission to possess, import or consume cannabis. Visitors should keep event attendance and applicable local rules separate when making plans.

Like our Florida CannFest music coverage, this preview follows the actual program rather than treating cannabis culture as a loose label. Tokyo’s draw is a specific screening within a continuing film forum. For now, interested readers can bookmark the organizer’s pages and distinguish the in-person anniversary event from the competition films. That makes it easier to follow updates without mistaking an anticipated opening date for an available booking. The next details to watch are tickets, confirmed scheduling and the opening of the separate online viewing program.

Illustrative stock cinema photograph; not LOFT9 Shibuya or a TICFF screening. Photo: Tima Miroshnichenko / Pexels.

A Massachusetts supplemental-budget proposal could change how some military veterans enter the state’s medical cannabis program. A Senate committee amendment would allow the Cannabis Control Commission to use Veterans Administration diagnosis records when issuing a registration card, without requiring a separate healthcare professional’s cannabis certification.

The proposal is not law. As of November 3, the official legislative record places the House bill and Senate amendment in the Orders of the Day for Thursday, November 5. For veterans following cannabis access, the important development is a proposed change to documentation—not a new card application route already available today.

What the amendment would do

Tom Angell’s November 3 reporting for Marijuana Moment highlights the medical-cannabis provisions within a much broader appropriations measure. The operative Senate language appears in amendment S.3290, rather than a standalone bill devoted only to cannabis.

Section 67 addresses a veteran receiving healthcare at a Veterans Administration facility who provides official VA documentation indicating a debilitating medical condition. It says the commission may issue a registration card and shall not require a written or electronic certification from a healthcare professional for that route.

The wording is narrower than a promise of automatic eligibility for every person who served. It identifies a healthcare setting, official documentation and a qualifying diagnosis. The commission’s proposed authority to issue a card should not be paraphrased as a guarantee that every veteran would immediately receive one.

The qualifying-condition change is separate

Section 66 would add post-traumatic stress disorder, a medical condition producing chronic pain, and opioid use disorder to the statutory definition of a debilitating medical condition. Those additions concern the state program’s legal eligibility framework. They are not new clinical-trial results demonstrating that cannabis treats each condition.

That distinction is useful for patients comparing political and medical news. A legislature can change an access requirement without resolving questions about the most appropriate treatment for an individual. A diagnosis, permission to register and a clinician’s treatment judgment remain different parts of a person’s care.

Where the legislation stands

The official history for H.5700 records House engrossment on October 21, followed by referral to Senate Ways and Means on October 26. On October 29, the committee recommended passage with replacement text, S.3290. The record then lists November 5 consideration.

Committee approval is a step in the legislative process, not the governor’s signature. The text can still change as the measure advances. Readers should therefore track the final language and any implementing instructions before assuming the documentary requirements have been altered.

The registration provision also sits inside a large budget bill covering many subjects. An update about that broader measure should be checked for the specific cannabis sections, rather than treated as confirmation that every earlier proposal survived intact.

There are three details to check in the next update: whether the Senate retains the veterans paragraph, whether the qualifying-condition additions remain, and whether the final measure becomes law. Following those separately prevents a general budget headline from being mistaken for confirmation that the patient-registration change has taken effect.

Why VA paperwork is central

The VA’s published guidance says its clinicians may discuss cannabis use with veterans but may not recommend medical marijuana or complete forms required for participation in state marijuana programs. That creates a practical distinction between discussing a diagnosis and signing a cannabis-specific recommendation.

The Massachusetts proposal would work with records of a qualifying diagnosis. It would not require VA clinicians to become state cannabis certifiers. Nor would a state-law change, on its own, rewrite the VA’s federal policies about pharmacies, payment or conduct on federal property.

The same VA guidance says cannabis use does not by itself cause a veteran to be denied VA benefits, and encourages discussion with providers. It also says the VA will not pay for medical marijuana and prohibits its use or possession on VA grounds. Those policies should not be confused with the state registration question.

A proposal to follow, not an application instruction

For now, applicants should rely on the Cannabis Control Commission’s current program instructions. News of a committee amendment is not a substitute for the procedure in force. The next useful reporting checkpoint is the Senate’s action and the exact text that continues through the legislative process.

Our coverage of botanical-drug evidence standards addresses another boundary worth preserving: access policy and proof of medical benefit are different questions. This Massachusetts proposal concerns access paperwork. Its significance lies in whether veterans could use existing diagnosis documentation instead of obtaining another cannabis certification—not in a claim that cannabis is suitable for everyone.

Massachusetts State House in a stock winter photograph; not November 2026 conditions. Photo: Phil Evenden / Pexels.